Stroke
Conditions
Keywords
SMARTCap
Brief summary
The hypothesis is that a stroke causes release of purines from brain into blood and that this is a very early biomarker of brain ischaemia. The investigators propose a simple blood test of substances (the purines) that result from cellular metabolism and are produced in excess when brain cells are starved of oxygen and glucose (as occurs during a stroke).
Detailed description
In this study, the investigators propose to use newly developed biosensor technology (SMARTCap) to directly address whether purines are indicators of real strokes, and can distinguish strokes from other conditions with similar symptoms, more rapidly.
Interventions
DEVICESMARTCap
The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
Sponsors
University Hospitals Coventry and Warwickshire NHS Trust
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. Stroke patients: Admitted to the Hyperacute Stroke Unit having a suspected stroke within 1 hour of admission. Important to note that not all these patients will have suffered a stroke 2. Control participants: Relatives of patients admitted to the stroke treatment pathway, who are healthy and have no signs of cardiovascular illness 3. Healthy volunteers
Exclusion criteria
1. Stroke patients: Delay in admission exceeds the time window of 4 hours between stroke symptoms and admission 2. Control participants: Obvious signs or history of cerebrovascular disease 3. Unhealthy volunteers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the levels of purine in the blood in Stroke patients compared to non-stroke patients (Healthy controls) | 30 minutes down to 5 minutes |
Secondary
| Measure | Time frame |
|---|---|
| To identify ischaemic versus haemorrhagic strokes by combining purine measurements and CT scans | 24 hours to 7 days |
Other
| Measure | Time frame |
|---|---|
| To measure the change in purines and their variability in control patients from baseline to day 7 | 24 hours - 7 days |
Countries
United Kingdom
Outcome results
None listed